AMAG Pharmaceuticals, Inc. (AMAG)
Stock Price Chart
Key Info
| Market Cap | 477.47M |
| Revenue (ttm) | 303.03M |
| Net Income (ttm) | -229.17M |
| Shares Out | 34.48M |
| EPS (ttm) | -6.77 |
| PE Ratio | n/a |
| Forward PE | 30.49 |
| Dividend | n/a |
| Dividend Yield | n/a |
Stock Quote
| Trading Day | Nov 16, 2020 |
| Last Price | $13.75 |
| Previous Close | $13.75 |
| Change ($) | 0.00 |
| Change (%) | 0.00% |
| Day's Open | - |
| Day's Range | 13.75 - 13.76 |
| Day's Volume | 0 |
| 52-Week Range | 4.41 - 13.80 |
More Stats
| Market Cap | 477.47M |
| Enterprise Value | 619.30M |
| Earnings Date (est) | n/a |
| Ex-Dividend Date | n/a |
| Shares Outstanding | 34.48M |
| Float | 33.75M |
| EPS (basic) | -6.74 |
| EPS (diluted) | -6.77 |
| FCF / Share | -0.66 |
| Dividend | n/a |
| Dividend Yield | n/a |
| Earnings Yield | n/a |
| FCF Yield | n/a |
| Payout Ratio | n/a |
| Shares Short | 6.29M |
| Short Ratio | 1.83 |
| Short % of Float | 18.64% |
| Beta | 0.87 |
| PE Ratio | n/a |
| Forward PE | 30.49 |
| P/FCF Ratio | n/a |
| PS Ratio | 1.58 |
| PB Ratio | 1.86 |
| Revenue | 303.03M |
| Operating Income | -220.14M |
| Net Income | -229.17M |
| Free Cash Flow | -22.73M |
| Net Cash | -141.83M |
| Net Cash / Share | -4.08 |
| Gross Margin | 73.09% |
| Operating Margin | -72.65% |
| Profit Margin | -75.60% |
| FCF Margin | -7.50% |
| ROA | -3.06% |
| ROE | -62.88% |
| ROIC | -58.20% |
Analyst Forecasts
Analyst Consensus: Overweight
Financial Performance
Financial Overview
| Year | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 327 | 472 | 494 | 432 | 418 | 124 | 80.86 | 85.38 | 61.25 | 66.25 |
| Revenue Growth | -30.82% | -4.44% | 14.22% | 3.4% | 236.28% | 53.83% | -5.3% | 39.39% | -7.54% | - |
| Gross Profit | 219 | 256 | 333 | 336 | 330 | 104 | 68.90 | 71.16 | 50.72 | 58.64 |
| Operating Income | -447 | -49.00 | -306 | 85.08 | 111 | -3.84 | -11.62 | -17.42 | -79.79 | -82.99 |
| Net Income | -468 | -68.50 | -201 | -2.48 | 32.78 | 136 | -9.60 | -16.75 | -77.07 | -81.15 |
| Shares Outstanding | 34.03 | 34.39 | 34.91 | 34.35 | 31.47 | 22.42 | 21.70 | 21.39 | 21.19 | 20.81 |
| Earnings Per Share | -13.74 | -1.99 | -5.75 | -0.07 | 0.93 | 5.45 | -0.44 | -0.78 | -3.64 | -3.90 |
| EPS Growth | - | - | - | - | -82.94% | - | - | - | - | - |
| Operating Cash Flow | -126 | 60.80 | 107 | 246 | 95.98 | 11.41 | -6.77 | -1.16 | -63.80 | -1.53 |
| Capital Expenditures | -2.54 | -2.53 | -8.99 | -5.46 | -1.26 | -0.04 | 1.34 | -0.05 | -0.51 | -1.22 |
| Free Cash Flow | -128 | 58.27 | 97.61 | 241 | 94.72 | 11.37 | -5.44 | -1.20 | -64.31 | -2.75 |
| Cash & Equivalents | 172 | 405 | 300 | 582 | 469 | 147 | 217 | 228 | 213 | 261 |
| Total Debt | 301 | 283 | 735 | 987 | 992 | 495 | - | - | - | - |
| Net Cash / Debt | -129 | 121 | -435 | -405 | -523 | -349 | 217 | 228 | 213 | 261 |
| Assets | 791 | 1,175 | 1,900 | 2,478 | 2,476 | 1,389 | 265 | 258 | 267 | 336 |
| Liabilities | 511 | 434 | 1,110 | 1,544 | 1,544 | 929 | 93.05 | 85.34 | 86.63 | 90.79 |
| Book Value | 280 | 742 | 790 | 934 | 932 | 460 | 172 | 173 | 181 | 245 |
Company Profile
Company Details
| Full Name | AMAG Pharmaceuticals, Inc. |
| Country | United States |
| Employees | 440 |
| CEO | Scott D. Myers |
Stock Information
| Ticker Symbol | AMAG |
| Stock Exchange | NASDAQ |
| Sector | Healthcare |
| Industry | Biotechnology |
| Unique Identifier | NASDAQ: AMAG |
Description
AMAG Pharmaceuticals, a pharmaceutical company, develops, manufactures, and commercializes therapeutics for maternal and women's health, and anemia management in the United States. The company markets Feraheme (ferumoxytol), an intravenous iron replacement therapeutic agent for the treatment of iron deficiency anemia in adult patients who have intolerance to oral iron or have had unsatisfactory response to oral iron, as well as patients who have chronic kidney disease; Makena, a hydroxyprogesterone caproate injection to reduce the risk of preterm birth in women pregnant with a single baby who have a history of singleton spontaneous preterm birth; Intrarosa(prasterone) vaginal insert steroid for the treatment of dyspareunia due to menopause; and Vyleesi (bremelanotide), an auto-injector device for the treatment of hypoactive sexual desire disorder in pre-menopausal women. Its product candidates also include AMAG-423 (ovine), an antibody fragment, which is in Phase 2b/3a trial for the treatment of severe preeclampsia in pregnant women; and Ciraparantag, an anticoagulant reversal agent that is in planned Phase 2b trial for the treatment of novel oral anticoagulants or low molecular weight heparin. The company sells Feraheme to authorized wholesalers and specialty distributors. The company has license agreements with Endoceutics, Inc., Palatin Technologies, Inc., Velo Bio, LLC, Prasco, LLC, Perosphere Pharmaceuticals Inc., and Antares Pharma, Inc. AMAG Pharmaceuticals, Inc. was founded in 1981 and is headquartered in Waltham, Massachusetts. As of November 12, 2020, AMAG Pharmaceuticals, Inc. operates as a subsidiary of Covis Group S.à r.l.